Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)

NCT02204475 | Withdrawn Phase 3

• 2 other identifiers: 5172-0662014-001841-25
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a randomized, multi-site, open-label trial of a fixed-dose combination of Grazoprevir (MK-5172) and Elbasvir (MK-8742) versus Boceprevir (BOC) / Pegylated Interferon (P) and Ribavirin (R) in treatment-naive and prior treatment failure genotype (GT) 1 hepatitis C virus (HCV)-infected participants. The primary hypothesis is that the proportion of treatment-naive (TN) and prior treatment failure (PTF) participants treated with grazoprevir + elbasvir achieving sustained virologic response (undetectable HCV ribonucleic acid \[RNA\]) 12 weeks after the end of study therapy (SVR12) will be greater than the proportion of BOC/PR-treated participants achieving SVR12.

Conditions

Hepatitis C

Outcome Measures

Primary Outcomes (1)

• Proportion of participants achieving SVR12

  Up to Week 60

Secondary Outcomes (4)

• Proportion of TN participants achieving SVR12

  Up to Week 60

• Number of participants experiencing an adverse event (AE)

  Up to Week 72

• Number of participants withdrawing from study treatment due to AEs

  Up to Week 72

• Proportion of PTF participants achieving SVR12

  Up to Week 60

Study Arms (2)

BOC/PR

ACTIVE COMPARATOR

All participants begin treatment with a 4-week lead-in of PR followed by 24 weeks of BOC/PR. At Treatment Week (TW) 28 TN participants who have undetectable HCV RNA at TW 8 will complete BOC/PR therapy. At TW 28 TN participants who have detectable HCV RNA at TW 8, as well as prior relapsers and prior partial responders, will continue on BOC/PR for an additional 8 weeks and then continue on PR for an additional 12 weeks. At TW 28 all cirrhotics and previous null responders will continue on BOC/PR for an additional 20 weeks.

Drug: Boceprevir; Drug: PegIntron; Drug: Ribavarin

Grazoprevir/Elbasvir

EXPERIMENTAL

Participants will undergo treatment with grazoprevir 100 mg + elbasvir 50 mg for 12 weeks.

Drug: Grazoprevir/Elbasvir

Interventions

Grazoprevir/Elbasvir DRUG

Participants take a fixed-dose combination of grazoprevir 100 mg and elbasvir 50 mg once daily (QD) by mouth (PO).

Grazoprevir/Elbasvir

Boceprevir DRUG

Participants take Boceprevir (BOC) 800 mg three times daily (TID) PO.

BOC/PR

PegIntron DRUG

Participants take 1.5 mcg/kg PegIntron (P) once weekly (QW) via subcutaneous injection.

Also known as: Pegylated Interferon

BOC/PR

Ribavarin DRUG

Participants take Ribavarin (R) 800-1400 mg (depending on body weight) twice daily (BID) PO.

BOC/PR

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Has HCV RNA ≥ 10,000 IU/mL at the time of screening
• Has documented chronic HCV GT 1 with no evidence of non-typeable or mixed GT infection
• Is cirrhotic or non-cirrhotic
• Has HCV treatment status that is treatment naïve, PR null responder; PR partial responder; or prior PR relapser
• If human immunodeficiency virus (HIV) co-infected (HIV-1) must be naïve to treatment with any antiretroviral therapy (ART) and have no plans to initiate ART treatment while participating in this trial, or be on HIV ART for at least 8 weeks prior to trial entry (no changes in HIV regimen are allowed within 4 weeks of registration); must also have at least one viable antiretroviral therapy alternative beyond their current regimens in the event of HIV virologic failure and the development of antiretroviral drug resistance
• Use an acceptable method of contraception or not be of childbearing potential

You may not qualify if:

• Has evidence of decompensated liver disease manifested by the presence of or history of ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy or other signs or symptoms of advanced liver disease
• Is co-infected with hepatitis B virus (e.g., hepatitis B surface antigen \[HBsAg\] positive)
• Has a history of malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer or carcinoma in situ; or is under evaluation for other active or suspected malignancy
• Has cirrhosis and liver imaging within 6 months of Day 1 showing evidence of hepatocellular carcinoma (HCC) or is under evaluation for HCC
• Has pre-existing psychiatric condition(s)
• Has clinically-relevant drug or alcohol abuse within 12 months of screening
• Is a female and is pregnant or breast-feeding, or expecting to become pregnant or donate eggs from Day 1 throughout treatment and until at least 6 months after the last dose of study medication, or longer if dictated by local regulations; or is a male subject and is planning to impregnate or provide sperm donation
• Has any preexisting condition or prestudy laboratory abnormality, electrocardiogram (ECG) abnormality or history of any illness, which, in the opinion of the investigator, might confound the results of the trial or pose additional risk in administering the study drug(s) to the subject
• Has a life-threatening severe AE (SAE) during the screening period
• Has evidence of history of chronic hepatitis not caused by HCV, including but not limited to nonalcoholic steatohepatitis (NASH), drug-induced hepatitis, and autoimmune hepatitis

Sponsors & Collaborators

• Merck Sharp & Dohme LLC: lead

MeSH Terms

Conditions

Hepatitis C

Interventions

elbasvir-grazoprevir drug combination; N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; peginterferon alfa-2b

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Hepatitis, Viral, Human; Virus Diseases; Flaviviridae Infections; RNA Virus Infections; Hepatitis; Liver Diseases; Digestive System Diseases

Study Officials

• Medical Director

  Merck Sharp & Dohme LLC

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 28, 2014
• First Posted: July 30, 2014
• Study Start: November 1, 2014
• Primary Completion: June 1, 2016
• Study Completion: September 1, 2016
• Last Updated: October 14, 2015

Record last verified: 2015-10